Release Date: Wednesday, December 13, 2017
Expiration Date: Thursday, December 13, 2018

Educational Overview
Opioid-induced constipation (OIC) is one of the most common and troublesome adverse events associated with the use of opioid medications for chronic cancer and noncancer pain. In addition to the clinical consequences, OIC is also associated with diminished quality of life, compromised pain management, and increased use of healthcare resources. For many clinicians, laxatives remain the first-line treatment in preventing and managing OIC, but these agents are associated with significant limitations and risks. Newer treatment options allow for a more targeted approach that specifically counteracts the gastrointestinal effects of opioids. As the role of health-system pharmacists in managing patients with chronic pain grows within the interdisciplinary team, it is imperative that pharmacists improve their competence and skills in the prevention and treatment of OIC. This includes utilizing effective prevention strategies, recognizing the early signs of OIC, evaluating severity of OIC, and selecting the optimal approach to treat OIC based on patient-specific factors. This program provides an overview of the burden and pathophysiology of OIC and offers practical solutions in the prevention and treatment of OIC through case-based discussions.

Target Audience
This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, community pharmacies, and academia. This program targets pharmacists who are involved in the management of patients who are taking opioid medications and may be at risk for OIC.


Learning Objectives
Those attending the program will be able at its conclusion to:

  • Discuss the impact of opioid-induced constipation (OIC) on a patient’s quality of life and overall well-being
  • Utilize evidence-based approaches to prevent OIC among patients initiating or continuing opioid analgesic treatment for chronic pain.
  • Evaluate the use of newer, non-laxative pharmacotherapies in the management of OIC based on OIC severity and patient preferences

Educational Format

This Online Presentation is based on the satellite symposium presented at the 52nd ASHP Midyear Clinical Meeting and Exhibition. It includes the following sections:

  • Opioid-Induced Constipation: The Pharmacist’s Role
  • Pathophysiology and Prevention of OIC
  • Knowing the Treatment Options

Note: If you have received credit for attending the live program by the same name, you are not eligible to apply for credit for this online version.



Gregory L. Holmquist, PharmD, CPE

Pain and Palliative Care Specialist
Certified Pain Educator
Palliative Care Strategies

Seattle, WA





AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credits for participating in this activity.
 ACPE UAN: 0473-9999-17-016-H01-P
Activity type: Knowledge-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit


Disclosure of Conflicts of Interest
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.



Gregory Holmquist, PharmD has relevant financial relationships with the following commercial interests:
Speakers Bureau: Salix, a Division of Valeant Pharmaceuticals North
        America and Daiichi-Sankyo
Dr. Homquist does not discuss off-label uses of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2017 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by an educational grant from Salix, a Division of
Valeant Pharmaceuticals North America.

By clicking below, I acknowledge that I have read the entire CE information.